How many stocks are there of Stereotaxis?
The current number of stocks of Stereotaxis is 80.7 M undefined.
Stereotaxis Stocks 2024
Stereotaxis Stocks
80.7 M
Ticker
STXS
ISIN
US85916J4094
WKN
A1J09L
In 2024, Stereotaxis had 80.7 M outstanding stocks, a 0% change from the 80.7 M stocks in the previous year.
The Stereotaxis Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2026e | 80.7 |
| 2025e | 80.7 |
| 2024e | 80.7 |
| 2023 | 80.7 |
| 2022 | 76.06 |
| 2021 | 75.56 |
| 2020 | 72.75 |
| 2019 | 63.05 |
| 2018 | 52.08 |
| 2017 | 22.61 |
| 2016 | 21.81 |
| 2015 | 21.11 |
| 2014 | 19.95 |
| 2013 | 11.55 |
| 2012 | 7.61 |
| 2011 | 6.01 |
| 2010 | 5.54 |
| 2009 | 4.75 |
| 2008 | 4.01 |
| 2007 | 3.92 |
| 2006 | 3.62 |
| 2005 | 2.99 |
| 2004 | 1.26 |
Stereotaxis shares outstanding US85916J4094 · A1J09L
The number of shares was Stereotaxis in 2023 — This indicates how many shares 80.702 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Stereotaxis earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Stereotaxis's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Stereotaxis’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Stereotaxis's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 1.26 M Aktien |
| 2005 | 2.99 M Aktien |
| 2006 | 3.62 M Aktien |
| 2007 | 3.92 M Aktien |
| 2008 | 4.01 M Aktien |
| 2009 | 4.75 M Aktien |
| 2010 | 5.54 M Aktien |
| 2011 | 6.01 M Aktien |
| 2012 | 7.61 M Aktien |
| 2013 | 11.55 M Aktien |
| 2014 | 19.95 M Aktien |
| 2015 | 21.11 M Aktien |
| 2016 | 21.81 M Aktien |
| 2017 | 22.61 M Aktien |
| 2018 | 52.08 M Aktien |
| 2019 | 63.05 M Aktien |
| 2020 | 72.75 M Aktien |
| 2021 | 75.56 M Aktien |
| 2022 | 76.06 M Aktien |
| 2023 | 80.7 M Aktien |
| 2024e | 80.7 M Aktien |
| 2025e | 80.7 M Aktien |
| 2026e | 80.7 M Aktien |
Stereotaxis Aktienanalyse
What does Stereotaxis do?
Stereotaxis Inc, based in St. Louis, Missouri, is a company that specializes in the development and marketing of advanced instruments and services in magnetic resonance imaging (MRI) and electrophysiology (EP). The company was founded in 1990 and its mission is to improve the accuracy, safety, and efficiency of MRI and EP procedures. The business model of Stereotaxis is based on providing a comprehensive range of systems, instruments, and services to support hospitals and clinics in performing MRI and EP procedures. The company focuses on developing innovative technologies and solutions to improve clinical outcomes and provide the best possible treatment for patients. The company has four main divisions: magnetic resonance imaging (MRI), electrophysiology (EP), cardiovascular diagnostics, and cardiology. In the MRI division, the company offers a variety of instruments and systems specifically designed for MRI procedures. This includes magnetic field control systems, imaging systems, sample collection and analysis instruments, and controls to make MRI procedures more efficient. In the electrophysiology division, Stereotaxis offers instruments and systems that facilitate the navigation and control of medical devices during EP procedures. This includes magnetic field controls and other technologies to improve the accuracy of catheter placement and increase safety during procedures. Stereotaxis's cardiovascular diagnostics division offers various services and technologies that facilitate the performance of cardiology procedures. This includes a comprehensive diagnostic platform that allows for the analysis of heart images. The cardiology division of Stereotaxis offers a comprehensive range of solutions to improve the performance of cardiology procedures in cardiology clinics and hospitals. This includes a range of technologies to improve the diagnosis and treatment of heart diseases. In recent years, Stereotaxis has developed a variety of innovative solutions and technologies to improve the performance of MRI and EP procedures. One example is Robotic Magnetic Navigation, a technology developed by the company to improve the accuracy and safety of EP procedures. This technology allows doctors to improve the navigation and control of catheters during procedures, thereby providing patients with increased treatment safety. Another example is Stereotaxis's Odyssey platform, a solution developed to enable real-time connectivity between various medical devices. This allows doctors to access a variety of information during procedures and make the performance of procedures more efficient. Overall, Stereotaxis has an impressive track record in the development and marketing of advanced solutions and technologies in the MRI and EP industry in recent years. With its innovative technology and comprehensive range of instruments and services, the company is well positioned to continue playing a key role in healthcare in the future. Stereotaxis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Stereotaxis's Shares Outstanding
Stereotaxis's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Stereotaxis’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Stereotaxis’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Stereotaxis’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Stereotaxis stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Stereotaxis are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Stereotaxis evolved in recent years?
The number of shares of Stereotaxis has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Stereotaxis as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Stereotaxis?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Stereotaxis pay?
Over the past 12 months, Stereotaxis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Stereotaxis is expected to pay a dividend of 0 USD.
What is the dividend yield of Stereotaxis?
The current dividend yield of Stereotaxis is .
When does Stereotaxis pay dividends?
Stereotaxis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Stereotaxis?
Stereotaxis paid dividends every year for the past 0 years.
What is the dividend of Stereotaxis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Stereotaxis located?
Stereotaxis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Stereotaxis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Stereotaxis from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.
When did Stereotaxis pay the last dividend?
The last dividend was paid out on 10/2/2024.
What was the dividend of Stereotaxis in the year 2023?
In the year 2023, Stereotaxis distributed 0 USD as dividends.
In which currency does Stereotaxis pay out the dividend?
The dividends of Stereotaxis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Stereotaxis
Our stock analysis for Stereotaxis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stereotaxis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
